Article Correctness Is Author's Responsibility: Anti-CD47 Antibody Granted Orphan Drug Designation for Multiple Myeloma

The article below may contain offensive and/or incorrect content.

The FDA has granted Orphan Drug designation to Surface Oncology's lead investigational candidate SRF231, a potential treatment for patients with multiple myeloma.